期刊文献+

地西他宾治疗32例骨髓增生异常综合征的临床疗效观察 被引量:6

下载PDF
导出
摘要 目的为了进一步研究地西他宾治疗骨髓增生异常综合征的临床实际效果,从而为相关研究提供借鉴之据。方法本文以我院2008年12月至2010年12月期间收治的骨髓增生异常综合征患者64例为研究对象,观察组患者采用地西他宾进行治疗,对照组患者采用亚砷酸进行治疗。观察比较两组患者实施不同临床治疗方法后的总体生存期和无病生存期以及患者的治疗前后的血管内皮生长因子水平。结果①在总体生存期和无病生存期两项指标上,组间比较,观察组患者的两项指标水平均显著的高于对组患者,且P均<0.05;②治疗后1d、3d、7d、14d,观察组患者的得分水平显著的优于对照组患者的得分水平,且组间比较P均<0.05。结论在临床治疗骨髓增生异常综合征的实践过程中,采用地西他宾进行治疗的临床效果显著,是临床治疗骨髓增生异常综合征的可靠选择。
作者 郑冬丽
出处 《中国医药指南》 2013年第31期485-486,共2页 Guide of China Medicine
  • 相关文献

参考文献8

二级参考文献58

  • 1徐泽锋,肖志坚.地汐他滨治疗骨髓增生异常综合征的研究进展[J].中华血液学杂志,2007,28(1):61-64. 被引量:4
  • 2Vardiman JW,Thiele J,Arber DA,et al.The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia:rationale and important changes.Blood,2009,114:937-951.
  • 3Babicka L,Ransdorfova S,Brezinova J,et al.Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH.Leuk Res,2007,31:39-47.
  • 4Steensma DP,Baer MR,Slaek JL,et al.How I treat patients with myelodysplastic syndromes.Blood,2009,113:6296-6303.
  • 5Issa J P. Epigenetic changes in the myelodysplastic syndrome[J]. HematolOncolClin North Am, 2010,24(2):317-330.
  • 6Herman J G, Baylin S B. Gene silencing in cancer in associationwith promoter hyper-methylation[J]. N Engl J Med, 2003,349(18):2042-2054.
  • 7David P,Steensma, Maria R, et al. Multicenter Study of Decit-abine Administered Daily for 5 Days Every 4 Weeks to AdultsWith Myelodysplastic Syndromes: The Alternative Dosing forOutpatient Treatment (ADOPT) Trial[J]. Clin Oncol, 2009,27(23):3842-3848.
  • 8Martens J W, Margossian A L, Schmitt M, et al. DNA methyl-ation asa biomarker in breast cancer[J]. Future Oncol, 2009,5(8):1245-1256.
  • 9Fernandez S V, Snider K E, Wu Y Z, et al. DNA methylationchanges in a human cell model of breast cancer progression[J].Mutat Res, 2010, 688(1 2) :28-35.
  • 10Hurtubise A, Momparler R L. Effect of histone deactylase in-hibitor LAQ824 on antineoplastic action of 5-azi20-deoxycyti-dine (decitabine) on human breast carcinoma cells [J]. CancerChemother Pharmacol, 2006,58(5) : 618-625.

共引文献83

同被引文献47

  • 1伏媛,朱华渊,徐佳岱,谌廷妹,吴微,钱思轩,李建勇,刘澎.地西他滨联合半剂量CAG方案治疗骨髓增生异常综合征[J].实用老年医学,2013,27(6):470-473. 被引量:6
  • 2王战营,郭宏岗,张莳,等.HAG方案治疗老年急性髓系白血病16例疗效分析[J].中国医师进修杂志,2012,9(35):57-58.
  • 3吴功强.傅祝能.地西他滨治疗老年急性髓细胞白血病及骨髓增生异常综合症5例报道[C].浙江省科学技术协会,2013.
  • 4Greenberg P,Cox C,Le Beau MM,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes[J].Blood,1997,89(6):2079-2088.
  • 5Mufti GJ,Bennett JM,Goasguen J,et al.Diagnosis and classification of myelodysplastic syndrome:International Working Group on Morphology of myelodysplastic syndrome(IWGM-MDS)consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts[J].Haematologica,2008,93(11):1712-1717.
  • 6Valent P,Horny HP,Bennett JM,et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic synd romes:Consen-susstatements and report from a working conference[J].Leuk Res,2007,31(6):727-736.
  • 7National Cancer Institute.Cancer therapy evaluation program common toxicity criteria[J].Cancer,1999,4:30.
  • 8Arthur C,Cermak J,Delaunay J,et al.Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia[J].J Blood Med,2015,8(6):25-29.
  • 9何广胜,吴德沛,孙爱宁,梁建英,刘丹丹,陈子兴,薛永权,阮长耿.WHO 2008年骨髓增生异常综合征诊断与分型修订解读[J].中国实用内科杂志,2010,30(5):416-421. 被引量:43
  • 10刘娟,王东江,王京华.骨髓增生异常综合征患者骨髓涂片的免疫表型分析[J].国际免疫学杂志,2010(5):415-416. 被引量:4

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部